Danshensu

• UNSPSC Description:

  Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

• Target Antigen:

  Apoptosis; Keap1-Nrf2; NF-κB; Reactive Oxygen Species; SARS-CoV

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Danshensu.html

• Purity:

  98.59

• Solubility:

  DMSO : < 1 mg/mL|H2O : 5 mg/mL (ultrasonic)

• Smiles:

  OC1=C(C=CC(C[C@H](C(O)=O)O)=C1)O

• Molecular Weight:

  198.174

• References & Citations:

  [1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43(4):771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne). 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  76822-21-4